Original article
Treatment of cutaneous hemangiomas by the flashlamp-pumped pulsed dye laser: Prospective analysis

https://doi.org/10.1016/S0022-3476(05)82481-3Get rights and content

Thirty-three cutaneous capillary and mixed hemangiomas in 24 patients were treated prospectively with the flashlamp-pumped pulsed dye laser. Patients ranged in age from 2 weeks to 7 months; the follow-up period was up to 22 months. Some patients received therapy until the lesion was almost clear or until the lesion failed to respond; others received treatment only until active capillary lesional proliferation abated. In the first group of patients, 18 of 25 lesions that were 3 mm or less in elevation lightened with therapy (93.9%±4.6% in 4.1±1.6 treatment sessions) and flattened to 0.3±0.4 mm in thickness. The seven lesions that were 4 mm or more in thickness lightened 85.7%±7.3% in 7.0±2.0 treatment sessions but showed less diminution in thickness (to 3.4±3.6 mm; p<0.01). The second group of patients, who received therapy until proliferation ceased, required just one to three therapeutic sessions. Three of the four lesions that showed residual atrophy were 4 mm or greater in thickness; the fourth lesion was ulcerated on presentation. None of the lesions had residual induration or scarring. We conclude that the flashlamp-pumped pulsed dye laser may successfully prevent enlargement and promote involution of capillary hemangiomas with minimal adverse effects. Therapy is most appropriate for patients with hemangiomas at sites of potential functional impairment, of maceration or ulceration, and of significant cosmetic disfigurement. Therapy should be initiated as early as possible, when lesions are relatively fiat, for optimal results.

References (17)

There are more references available in the full text version of this article.

Cited by (183)

  • Lid and orbital infantile periocular hemangiomas (capillary hemangiomas) and other vascular diseases

    2016, Taylor and Hoyt's Pediatric Ophthalmology and Strabismus, Fifth Edition
  • Evidence-Based Medicine in the Treatment of Infantile Hemangiomas

    2015, Facial Plastic Surgery Clinics of North America
    Citation Excerpt :

    PDLs are generally well tolerated—side effects of their use for treatment of IHs include temporary local swelling, hyper- or hypopigmentation, and rarely pain, scarring, ulceration, or hemorrhage.75 The PDL has been used and studied for more than 30 years as an option for treatment of IHs, and, as a result, there is substantial level III–V evidence in the form of various case reports, retrospective reviews, and small, nonrandomized prospective studies supporting its efficacy in the literature.76–83 In 2002, the first level III evidence comparing PDL therapy to observation in the treatment of IHs was performed by Batta and colleagues84 and raised significant doubt surrounding its efficacy.

  • Current status of surgery in dermatology

    2013, Journal of the American Academy of Dermatology
  • Vascular anomalies in maxillofacial region-Review

    2012, Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
View all citing articles on Scopus
View full text